Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Launched by NATIONAL CANCER INSTITUTE (NCI) · Feb 24, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of adding two targeted therapies, trastuzumab (also known as Herceptin) and pertuzumab, to standard chemotherapy for women with certain types of uterine cancer that are HER2 positive. The usual chemotherapy used in this study includes paclitaxel and carboplatin, which work to stop cancer cells from growing. By combining these treatments, the researchers hope to see if they can shrink tumors more effectively and reduce the chances of the cancer coming back.
To be eligible for this trial, participants must be women aged 18 or older with a confirmed diagnosis of HER2 positive endometrial serous carcinoma or carcinosarcoma, and they should not have received any previous chemotherapy for this type of cancer. Patients should be within 8 weeks of their primary surgery and have tumors that can be measured. The study is currently recruiting participants, and those who join can expect to receive the combination of treatments and be monitored closely for their response to therapy and any side effects. It's important for potential participants to discuss with their doctors to see if this trial is a good option for them.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- * Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial cancer. The following endometrial cancer types are eligible:
- • Serous
- • Other endometrial cancers (including clear cell, endometrioid, mixed epithelial, dedifferentiated/undifferentiated)
- • Carcinosarcoma
- • NOTE: Endometrial cancers that are mismatch repair deficient (dMMR) by IHC are not eligible
- • Histologic confirmation of the original primary tumor is required. Submission of surgical pathology report (or endometrial biopsy pathology report in patients who never undergo hysterectomy) is required
- • Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration
- • Patients may have measurable disease, non-measurable disease, or no measurable disease. In patients with measurable disease, lesions will be defined and monitored by RECIST v 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \>= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be \>= 15 mm in short axis when measured by CT or MRI
- • For patients with uterine-confined (stage I) disease, the tumor must be invasive into the myometrium. Any amount of myoinvasion is acceptable for eligibility. Patients with non-invasive disease, endometrial intraepithelial carcinoma alone, or disease confined to a polyp will be excluded
- * All patients must have tumors that are HER2 positive as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 Breast Cancer guidelines (https://documents.cap.org/documents/algorithim-evaluation-her2.pdf.) IHC and ISH testing will be done locally, at each participating institution and interpreted by local pathologists. In general HER2 positivity is defined as any of the following:
- • 3+ immunohistochemistry (IHC),
- • 2+ IHC with positive in situ hybridization (ISH) Alternatively, patients could be eligible if next generation sequencing (NGS) demonstrates HER2 (ERBB2) amplification. NGS testing can be performed through any designated labs as per the National Cancer Institute (NCI) MATCH/NCI Combo-MATCH trial (https://ecog-acrin.org/nci-match-eay131-designated-labs).
- • Pathology report showing results of institutional HER2 testing (or NGS testing results) must be submitted.
- • Sites must submit all results available (IHC, ISH, and NGS)
- • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- • Age \>= 18
- • Platelets \>= 100,000/mcl (within 14 days prior to registration)
- • Absolute neutrophil count (ANC) \>= 1,500/mcl (within 14 days prior to registration)
- • Creatinine =\< 1.5 x institutional/laboratory upper limit of normal (ULN) or estimated Glomerular filtration rate (eGFR) \>= 50 mL/min using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR) (within 14 days prior to registration)
- • Total serum bilirubin level =\< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =\< 3 x ULN may be enrolled) (within 14 days prior to registration)
- • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN (within 14 days prior to registration)
- • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial
- * Although the uterus will have been removed in the vast majority of patients, for patients of child-bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. Patients will be considered of non-reproductive potential if they are either:
- • Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women \< 45 years of age, a high follicle stimulating hormone \[FSH\] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
- • Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to registration
- • Have a congenital or acquired condition that prevents childbearing
- • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- • Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated
- • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
- • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
- Exclusion Criteria:
- * Prior Therapy:
- • Patients must NOT have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma
- • Patients must NOT have received prior radiation therapy for treatment of endometrial carcinoma. Prior radiation includes external beam pelvic radiation therapy, external beam extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy
- • NOTE: Vaginal brachytherapy for treatment of endometrial cancer is permitted during study treatment. Planned use of vaginal brachytherapy must be declared at time of registration
- • Patients may have received prior hormonal therapy for treatment of endometrial carcinoma. All hormonal therapy must be discontinued at least one week prior to registration
- • Patients may not have a planned interval cytoreduction or hysterectomy, prior to documentation of progression, after study registration
- • Patients may not have planned external beam radiotherapy, prior to documentation of progression, after study registration
- * Significant cardiovascular disease including:
- • Uncontrolled hypertension, defined as systolic \> 150 mm Hg or diastolic \> 90 mm Hg despite antihypertensive medications
- • Myocardial infarction or unstable angina within 6 months prior to registration
- • New York Heart Association functional classification II, III or IV
- • Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate
- • Significant lung disease: dyspnea at rest grade 2 or greater (resulting from extensive tumor involvement or other causes), pneumonitis grade 2 or greater, interstitial lung disease grade 2 or greater, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)
- • Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), uncontrolled interstitial lung disease, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements
- • Treatment with strong CYP2C8 or CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to registration
- • Women who are unwilling to discontinue nursing
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
New Haven, Connecticut, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Milwaukee, Wisconsin, United States
Charleston, South Carolina, United States
Springfield, Massachusetts, United States
Washington, District Of Columbia, United States
Saint Louis, Missouri, United States
Philadelphia, Pennsylvania, United States
Flint, Michigan, United States
Philadelphia, Pennsylvania, United States
Flint, Michigan, United States
Kalamazoo, Michigan, United States
Edina, Minnesota, United States
Sioux Falls, South Dakota, United States
Arlington Heights, Illinois, United States
South Bend, Indiana, United States
Toms River, New Jersey, United States
Little Rock, Arkansas, United States
Sarasota, Florida, United States
Hackensack, New Jersey, United States
Oklahoma City, Oklahoma, United States
Duarte, California, United States
La Crosse, Wisconsin, United States
New York, New York, United States
Long Branch, New Jersey, United States
Cleveland, Ohio, United States
Baltimore, Maryland, United States
Saint Paul, Minnesota, United States
West Chester, Pennsylvania, United States
Greeley, Colorado, United States
Loveland, Colorado, United States
Ann Arbor, Michigan, United States
Kalamazoo, Michigan, United States
Traverse City, Michigan, United States
Bozeman, Montana, United States
Kalispell, Montana, United States
Lancaster, Ohio, United States
Chicago, Illinois, United States
Cincinnati, Ohio, United States
Dallas, Texas, United States
Atlanta, Georgia, United States
Chillicothe, Ohio, United States
Tualatin, Oregon, United States
Bryn Mawr, Pennsylvania, United States
Coon Rapids, Minnesota, United States
Urbana, Illinois, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
Dayton, Ohio, United States
Rapid City, South Dakota, United States
Sarasota, Florida, United States
Effingham, Illinois, United States
Mount Vernon, Ohio, United States
Bethlehem, Pennsylvania, United States
Springfield, Illinois, United States
Baltimore, Maryland, United States
Augusta, Maine, United States
Portland, Oregon, United States
Roseville, California, United States
Springfield, Illinois, United States
Media, Pennsylvania, United States
Washington, District Of Columbia, United States
Troy, Michigan, United States
Honolulu, Hawaii, United States
Rochester, New York, United States
Philadelphia, Pennsylvania, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Birmingham, Alabama, United States
Tucson, Arizona, United States
Modesto, California, United States
Sacramento, California, United States
Aurora, Colorado, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Bethesda, Maryland, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
Columbia, Missouri, United States
New Brunswick, New Jersey, United States
New York, New York, United States
New York, New York, United States
Syracuse, New York, United States
Chapel Hill, North Carolina, United States
Winston Salem, North Carolina, United States
Fargo, North Dakota, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
Mountain View, California, United States
Aurora, Illinois, United States
Camden, New Jersey, United States
Neptune, New Jersey, United States
Canton, Ohio, United States
Columbus, Ohio, United States
Tulsa, Oklahoma, United States
Allentown, Pennsylvania, United States
Morgantown, West Virginia, United States
Providence, Rhode Island, United States
Wyoming, Michigan, United States
Honolulu, Hawaii, United States
Evanston, Illinois, United States
Saint Louis Park, Minnesota, United States
Livingston, New Jersey, United States
Lima, Ohio, United States
Portland, Oregon, United States
Omaha, Nebraska, United States
Bethlehem, Pennsylvania, United States
Fort Lauderdale, Florida, United States
Royal Oak, Michigan, United States
Albuquerque, New Mexico, United States
Sioux Falls, South Dakota, United States
Dallas, Texas, United States
Richmond, Virginia, United States
Sacramento, California, United States
Augusta, Georgia, United States
Saint Louis, Missouri, United States
Mineola, New York, United States
Green Bay, Wisconsin, United States
Madison, Wisconsin, United States
Marshfield, Wisconsin, United States
Portland, Oregon, United States
Decatur, Illinois, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Austin, Texas, United States
New Haven, Connecticut, United States
Reed City, Michigan, United States
Maplewood, Minnesota, United States
Great Falls, Montana, United States
Toledo, Ohio, United States
Paoli, Pennsylvania, United States
Concord, California, United States
Los Angeles, California, United States
Walnut Creek, California, United States
Hartford, Connecticut, United States
Jupiter, Florida, United States
Atlanta, Georgia, United States
Ames, Iowa, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Battle Creek, Michigan, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Woodbury, Minnesota, United States
Springfield, Missouri, United States
Billings, Montana, United States
Billings, Montana, United States
Missoula, Montana, United States
Red Bank, New Jersey, United States
Voorhees, New Jersey, United States
Albany, New York, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Mentor, Ohio, United States
Sylvania, Ohio, United States
Toledo, Ohio, United States
Troy, Ohio, United States
Portland, Oregon, United States
East Stroudsburg, Pennsylvania, United States
Sioux Falls, South Dakota, United States
Roanoke, Virginia, United States
Green Bay, Wisconsin, United States
Minocqua, Wisconsin, United States
Oconomowoc, Wisconsin, United States
Oconto Falls, Wisconsin, United States
Rice Lake, Wisconsin, United States
Weston, Wisconsin, United States
Berkeley, California, United States
San Francisco, California, United States
Norwalk, Connecticut, United States
Savannah, Georgia, United States
Chicago, Illinois, United States
Albuquerque, New Mexico, United States
Marietta, Ohio, United States
Newark, Ohio, United States
Springfield, Ohio, United States
Westerville, Ohio, United States
Zanesville, Ohio, United States
Livonia, Michigan, United States
Newberg, Oregon, United States
Munster, Indiana, United States
Albuquerque, New Mexico, United States
Boise, Idaho, United States
Charleston, West Virginia, United States
Danbury, Connecticut, United States
Tucson, Arizona, United States
Saint Joseph, Michigan, United States
Torrington, Connecticut, United States
Council Bluffs, Iowa, United States
Boise, Idaho, United States
Indianapolis, Indiana, United States
Somerville, New Jersey, United States
Hinsdale, Illinois, United States
Warrenville, Illinois, United States
Lexington, Kentucky, United States
Austin, Texas, United States
Orange, California, United States
Atlanta, Georgia, United States
Carmel, Indiana, United States
Post Falls, Idaho, United States
Geneva, Illinois, United States
Scarborough, Maine, United States
Saint Louis, Missouri, United States
Houston, Texas, United States
Raleigh, North Carolina, United States
Goshen, Indiana, United States
Louisville, Kentucky, United States
Oklahoma City, Oklahoma, United States
Erie, Pennsylvania, United States
Aberdeen, South Dakota, United States
Roanoke, Virginia, United States
Irvine, California, United States
Panorama City, California, United States
Riverside, California, United States
Sunnyvale, California, United States
Atlanta, Georgia, United States
Fruitland, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Twin Falls, Idaho, United States
New Orleans, Louisiana, United States
Farmington Hills, Michigan, United States
Rolla, Missouri, United States
Fargo, North Dakota, United States
Beachwood, Ohio, United States
Chardon, Ohio, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Portsmouth, Ohio, United States
Monroeville, Pennsylvania, United States
Edmonds, Washington, United States
Vancouver, Washington, United States
New Richmond, Wisconsin, United States
Springfield, Illinois, United States
Belpre, Ohio, United States
Springfield, Ohio, United States
Great Falls, Montana, United States
Auburn, California, United States
Santa Cruz, California, United States
Newark, Delaware, United States
Newark, Delaware, United States
Caldwell, Idaho, United States
Coeur D'alene, Idaho, United States
Nampa, Idaho, United States
Sandpoint, Idaho, United States
Farmington Hills, Michigan, United States
Flint, Michigan, United States
Flint, Michigan, United States
Saginaw, Michigan, United States
West Branch, Michigan, United States
Anaconda, Montana, United States
Las Vegas, Nevada, United States
Centerville, Ohio, United States
Grove City, Ohio, United States
Ontario, Oregon, United States
Houston, Texas, United States
Sugar Land, Texas, United States
South Jordan, Utah, United States
Commack, New York, United States
Centralia, Illinois, United States
Danville, Illinois, United States
Decatur, Illinois, United States
Effingham, Illinois, United States
Mattoon, Illinois, United States
New Lenox, Illinois, United States
O'fallon, Illinois, United States
Yorkville, Illinois, United States
Marrero, Louisiana, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Ypsilanti, Michigan, United States
Las Vegas, Nevada, United States
Clackamas, Oregon, United States
Sturgeon Bay, Wisconsin, United States
Montvale, New Jersey, United States
Harrison, New York, United States
Uniondale, New York, United States
Middletown, New Jersey, United States
Glenview, Illinois, United States
Highland Park, Illinois, United States
Ames, Iowa, United States
Fort Dodge, Iowa, United States
Jefferson, Iowa, United States
Marshalltown, Iowa, United States
Basking Ridge, New Jersey, United States
Richmond, Virginia, United States
Baton Rouge, Louisiana, United States
Baton Rouge, Louisiana, United States
Westminster, Maryland, United States
Norton Shores, Michigan, United States
Henderson, Nevada, United States
Eau Claire, Wisconsin, United States
Wexford, Pennsylvania, United States
Richmond, Virginia, United States
Sewell, New Jersey, United States
Mukwonago, Wisconsin, United States
Waukesha, Wisconsin, United States
Trumbull, Connecticut, United States
Dallas, Texas, United States
Westlake, Ohio, United States
Orland Park, Illinois, United States
Jefferson Hills, Pennsylvania, United States
Edgewood, Kentucky, United States
Las Vegas, Nevada, United States
Lakewood, New Jersey, United States
Moorestown, New Jersey, United States
Rio Rancho, New Mexico, United States
Perrysburg, Ohio, United States
Willow Grove, Pennsylvania, United States
Metairie, Louisiana, United States
Seattle, Washington, United States
Fort Worth, Texas, United States
New York, New York, United States
Derby, Connecticut, United States
Fairfield, Connecticut, United States
North Haven, Connecticut, United States
Waterbury, Connecticut, United States
Waterford, Connecticut, United States
Dekalb, Illinois, United States
High Point, North Carolina, United States
Stevens Point, Wisconsin, United States
Greenwich, Connecticut, United States
Hazleton, Pennsylvania, United States
Bluffton, South Carolina, United States
Germantown, Tennessee, United States
Orlando, Florida, United States
Mooresville, Indiana, United States
Easton, Pennsylvania, United States
Lake Forest, Illinois, United States
Springfield, Ohio, United States
Upland, California, United States
Lafayette, Indiana, United States
San Juan, , Puerto Rico
Bozeman, Montana, United States
Baton Rouge, Louisiana, United States
Covington, Louisiana, United States
Irvine, California, United States
Stamford, Connecticut, United States
Crown Point, Indiana, United States
Dyer, Indiana, United States
Hobart, Indiana, United States
Hobart, Indiana, United States
Indianapolis, Indiana, United States
Munster, Indiana, United States
Valparaiso, Indiana, United States
Kalamazoo, Michigan, United States
Omaha, Nebraska, United States
Houston, Texas, United States
Nassau Bay, Texas, United States
Richardson, Texas, United States
The Woodlands, Texas, United States
Glastonbury, Connecticut, United States
Philadelphia, Pennsylvania, United States
Baton Rouge, Louisiana, United States
Westerly, Rhode Island, United States
Cary, North Carolina, United States
Highlands Ranch, Colorado, United States
Missoula, Montana, United States
Cary, North Carolina, United States
Venice, Florida, United States
Greeley, Colorado, United States
Nampa, Idaho, United States
Springfield, Illinois, United States
Perrysburg, Ohio, United States
Toledo, Ohio, United States
Denver, Colorado, United States
Long Beach, California, United States
Aurora, Colorado, United States
Seoul, Gyeongsangnam Do, Korea, Republic Of
Sheboygan, Wisconsin, United States
Fort Worth, Texas, United States
Mineola, New York, United States
Wilmington, North Carolina, United States
Indianapolis, Indiana, United States
Allentown, Pennsylvania, United States
Kalispell, Montana, United States
Greenville, North Carolina, United States
Wyoming, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Nampa, Idaho, United States
Pontiac, Michigan, United States
Danville, Illinois, United States
Huntington Beach, California, United States
Guilford, Connecticut, United States
Orland Park, Illinois, United States
Quakertown, Pennsylvania, United States
Greenville, Ohio, United States
Decatur, Georgia, United States
Boone, Iowa, United States
Fort Dodge, Iowa, United States
Jefferson, Iowa, United States
Marshalltown, Iowa, United States
Ames, Iowa, United States
Minocqua, Wisconsin, United States
Columbia, Missouri, United States
Sarasota, Florida, United States
Glenview, Illinois, United States
Grayslake, Illinois, United States
Marysville, Ohio, United States
Niles, Michigan, United States
Reed City, Michigan, United States
Saint Joseph, Michigan, United States
Billings, Montana, United States
Grand Rapids, Michigan, United States
Loveland, Colorado, United States
Concord, California, United States
Saint Joseph, Michigan, United States
Council Bluffs, Iowa, United States
Madison, Wisconsin, United States
Huntington Beach, California, United States
N. Venice, Florida, United States
Royal Oak, Michigan, United States
Sandpoint, Idaho, United States
Ontario, Oregon, United States
Farmington Hills, Michigan, United States
Troy, Michigan, United States
Saginaw, Michigan, United States
Tawas City, Michigan, United States
Crown Point, Indiana, United States
Madison, Wisconsin, United States
Flint, Michigan, United States
Sheboygan, Wisconsin, United States
Rolla, Missouri, United States
Venice, Florida, United States
Scarborough, Maine, United States
Patients applied
Trial Officials
Britt K Erickson
Principal Investigator
NRG Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials